Navigation Links
Nexcelom Bioscience to Distribute FCS Express 4 Cytometry Software with Cellometer Vision CBA Instruments
Date:10/11/2011

LOS ANGELES, Oct. 11, 2011 /PRNewswire/ -- De Novo Software™, a leading provider of flow and image cytometry data analysis solutions, and Nexcelom Bioscience, a leading supplier of cell counting and analysis products for bioresearch and drug discovery, announced today a licensing agreement enabling Nexcelom to distribute De Novo Software's flagship product, FCS Express 4 Software.  

Under the terms of the agreement, Nexcelom will distribute the FCS Express 4 Cytometry Software to customers in the research, biotech and pharmaceutical markets worldwide.  The FCS Express 4 Software can natively import Nexcelom Cellometer® Vision data for visualization of multi-parametric results.  

With the Cellometer Vision CBA Analysis System, a drop-down menu of assays with pre-set optical module selection, exposure time, and data calculation/presentation set-up make imaging and analysis simple and repeatable. With just 20 Microlitres of sample and a few clicks, users obtain fluorescent cell images, dot plots, and histograms in pre-optimized layouts for specific cell-based assays. Researchers can view cell morphology real-time and archive cell images along with comprehensive analysis reports.

According to Jean Qiu, CTO at Nexcelom, "FCS Express 4 is helping us to improve the overall end-user experience, enabling scientists to focus less on the plotting and formatting process and more on results. We are excited to offer a simple, microscopy-based platform for cell-based assays as an alternative to more complex fluidic instruments."

De Novo Software launched FCS Express 4 in January of 2011.  In addition to fully customized analysis and reporting, the new software adds the ability to analyze image based data.  These novel tools significantly improve assay development, workflow, and enable rapid report generation with image based assays.

David Novo, De Novo Software's president said: "This is an exciting collaboration and business relationship.  We look forward to providing options for flexible data analysis and reporting platform for the Nexcelom Cellometer® Vision customers."

Peter Li, CEO at Nexcelom said: "Seamless integration of FCS Express 4 provides state-of-the-art data reporting and applications support for the Cellometer cell based assays.  De Novo Software is a key strategic partner in our continued effort to provide total solutions to simplify current work flows for our customers."

Michael Sjaastad, Director of Business Development at De Novo Software commented, "There is an unmet need for a common analysis platform for all cytometry data.  We look forward to building upon this key relationship to provide a general platform for data analysis and report generation used by scientists worldwide."

For more information, visit www.denovosoftware.com or www.nexcelom.com


'/>"/>
SOURCE De Novo Software
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Teams with Animal Shelters to Improve Health and Enhance Immunity of Cats and Dogs
2. Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
3. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
4. Roka Bioscience Initiates External Trial for AOAC Certification
5. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
6. OBNs 2011 Annual Awards Dinner Celebrates UK Bioscience Success Stories
7. HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
8. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
9. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
10. BD Biosciences Announces Winners of Research Grant Program
11. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):